December 8th, 2014
New Anticoagulant Spotlights Major Role for the Intrinsic Pathway
Sanjay Kaul, MD and Ethan J Weiss, M.D.
Sanjay Kaul and Ethan Weiss discuss an entirely new approach to anticoagulation.
December 28th, 2011
No Mortality Benefit of Low-Molecular-Weight Heparin in Acutely Ill Patients
Larry Husten, PHD
Although venous thromboembolism (VTE) is a serious problem for acutely ill patients in the hospital, a new study published in the New England Journal of Medicine failed to find any improvement in mortality associated with thromboprophylaxis. Ajay Kakkar and the LIFENOX investigators randomized 8307 acutely ill patients to receive enoxaparin or placebo for 10 days. All patients wore elastic […]
April 5th, 2011
MAGELLAN: Higher Bleeding Rates Cloud Rivaroxaban’s Effect in VTE Prevention in Acutely Ill Medical Patients
Larry Husten, PHD
The novel anticoagulant rivaroxaban is successful in preventing venous thromboembolism (VTE) in acutely ill medical patients, but a high bleeding rate means the drug probably won’t be used for this indication. Alexander Cohen, presenting the results of the MAGELLAN trial at the ACC in New Orleans, explained by way of background that 50% to 70% […]
October 21st, 2010
News Briefs: Recurrent Stroke Prevention Guidelines, Vernakalant Trial Suspended, GSK Investigated, Generic Enoxaparin Takes Off, Kaul Speaks, Midei Sues
Larry Husten, PHD
The American Heart Association published revised recurrent stroke prevention guidelines. The new guidelines state that recurrent stroke may be prevented by carotid angioplasty or by treating metabolic syndrome. The FDA warned about arrhythmias tied to HIV therapy. The FDA today updated the label for Invirase (saquinavir), noting that when used in combination with Norvir (ritonavir) it […]
August 31st, 2010
Positive Results for Rivaroxaban in EINSTEIN-DVT
Larry Husten, PHD
The EINSTEIN-DVT study tested the effect of the new oral anticoagulant rivaroxaban in the setting of DVT. The open-label, non-inferiority study randomized more than 3,400 patients with acute, symptomatic DVT to either oral rivaroxaban or conventional therapy with enoxaparin followed by warfarin or acenocoumarol for 3, 6, or 12 months, based on the attending physician’s […]
July 23rd, 2010
FDA Approves Generic Enoxaparin
Larry Husten, PHD
The FDA announced on Friday that it had approved the first generic enoxaparin sodium injection for multiple indications including prevention of deep vein thrombosis (DVT). The action represents the FDA’s first generic approval of a low molecular weight heparin. The original version of enoxaparin, Lovenox, was first approved in 1993. To gain approval as a generic, […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?